Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Recce Pharmaceuticals - Executive Interview 

upload.jpg

Recce Pharmaceuticals is an Australian company developing its novel, broad-spectrum synthetic polymer anti-infective drugs for the treatment of several infectious diseases, including sepsis, burn wound infections, urinary tract infections/urosepsis and diabetic foot infections.


In this interview, CEO James Graham describes the company’s latest developments in advancing its lead compound RECCE® 327 (R327) to treat complex drug-resistant infections. He discusses Recce’s recent human data on the intravenous R327 formulation targeting urinary tract infections and sepsis/urosepsis, as well as upcoming clinical trial strategies in these areas. James also elaborates on the topical R327 formulation’s progress in skin and skin-structure infections and Recce’s plans to start a registrational Phase III trial in Indonesia for diabetic foot infections in the coming months.